Clinical Trials

Verified stories whose regulatory record supports clinical-trial access. Eligibility and enrollment are never guaranteed.

Filter clinical trials

Results

97 verified trial-access stories match your filters.

Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.

Trial Watch: Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Breast Cancer
Trial identifier
NCT06429761
Trial phase
Phase 4
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with BREAST CANCER who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-11

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-11

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Lung Cancer
Trial identifier
NCT06687369
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Non Squamous Non Small Cell Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-10

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-10

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Endometrial (Uterine) Cancer
Trial identifier
NCT07166094
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Endometrial Cancer, Recurrent or Progressive Endometrial Cancer who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed
2026-09-09

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-09

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Lung Cancer
Trial identifier
NCT06345729
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Non-small Cell Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-08

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-08

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Bladder Cancer
Trial identifier
NCT04628767
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Renal Pelvis and Ureter Urothelial Carcinoma who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-03

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-03

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Stomach (Gastric) Cancer
Trial identifier
NCT06203600
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8 who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-03

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-03

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator’s Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Lymphoma
Trial identifier
NCT06084936
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Lymphoma who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-03

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-03

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Breast Cancer
Trial identifier
NCT06790693
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Breast Cancer who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-03

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-03

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Pancreatic Cancer
Trial identifier
NCT04340141
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8 who meet the study-specific registry eligibility criteria.
Last reviewed
2026-09-02

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-02

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

Trial Watch: A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Regulatory status: InvestigationalEvidence stage: Later-Stage Human
Cancer type
Endometrial (Uterine) Cancer
Trial identifier
NCT06340568
Trial phase
Phase 3
View trial details
Study design
Other / not applicable
Population
Participants age 18 Years and older with Endometrial Cancer who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed
2026-09-01

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-09-01

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.